CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...